Cardiac Biomarkers Testing Market by Type (Myocardial Muscle Creatine Kinase, Troponins, Myoglobin, Brain Natriuretic Peptide, Ischemia-modified Albumin, and Others), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others) and Location of Testing (Point of care Testing and Laboratory Testing): Global Opportunity Analysis and Industry Forecast, 20192026
- Published Date: 2020-10-18
- Report ID: 3540
- Pages: 256
-
Format:
The global cardiac biomarker market generated $7,638 million in 2018, and is projected to reach $18,232 million by 2026, growing at a CAGR of 11.4%. Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state as well as for diagnostic and prognostic purposes associated with heart. The prevention of cardiac diseases by monitoring heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS), and others. The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA, and others. The global cardiac biomarkers testing market has witnessed a greater demand over the past five to six years.
The ability of cardiac markers for accurate and rapid prediction of heart failure after the onset of chest pain acts as a key factor that boosts the growth of the global cardiac market. In addition, promising features such as high accuracy, quick outcomes, and economic pricing of cardiac point of care (POC) testing drive the market growth. To keep the momentum of cardiac marker tests, key manufacturers offer customized solutions, thus propelling the growth of the market. The commercial application of multi-menu options for cardiac testing using different combinations of cardiac biomarkers and target-oriented solutions serves as the key opportunity for market expansion. However, limited specificity in some cases and side effects such as skeletal muscle injury restrain the growth of the cardiac biomarkers testing market.
The global cardiac biomarker market is segmented based on type, application, location of testing, and region. By type, the market is fragmented into myocardial muscle creatine kinase (CK-MB), troponins (T and I), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified albumin (IMA), and others. Depending on application, it is categorized into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. By location of testing, it is bifurcated into point of care testing and laboratory testing. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
This report highlights the market dynamics to understand the global cardiac biomarker market and capitalize on the prevailing opportunities.
Quantitative analysis of the current market and forecasts assists stakeholders to design business strategies accordingly.
Porter's five forces analysis examines the competitive market structure and provides a deeper understanding of the influencing factors for entry and expansion.
Pin-point analysis of geographical segments offers identification of most profitable segments to capitalize on.
KEY MARKET SEGMENTS
By Type
o Myocardial Muscle Creatine Kinase (CK-MB)
o Troponins (T and I)
o Myoglobin
o Brain Natriuretic Peptide (BNPs) or NT-proBNP
o Ischemia-modified Albumin (IMA)
o Others
By Application
o Myocardial Infarction
o Congestive Heart Failure
o Acute Coronary Syndrome
o Atherosclerosis
o Others
By Location of Testing
o Point of Care Testing
o Laboratory Testing
By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
Spain
Italy
UK
Rest of Europe
o Asia-Pacific
Australia
Japan
India
China
Rest of Asia-Pacific
o LAMEA
Latin America
Middle East
Africa
KEY MARKET PLAYERS
Roche Diagnostics
Abbott Laboratories
Siemens Healthcare
Becton, Dickinson and Company
Bio-Rad Laboratories
BioMerieux
PerkinElmer Inc.
Tosoh Corporation
Danaher Corporation
Thermo Fisher Scientific
The other players in the value chain include (profiles not included in the report):
Randox Laboratories
Johnson and Johnson
Olympus Corporation
BG Medicines
ACS Biomarker B.V.
Cavadis Biomedical.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings
2.1.1. Top impacting factors
2.1.2. Top investment pockets
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Biomarker diagnosis vs. conventional diagnosis
3.3. Assessment of key advantages and buying criteria for diagnostic biomarkers
3.3.1. Early diagnosis
3.3.2. Tissue specific diagnosis
3.3.3. Reduce clinical trials
3.3.4. Consistent output
3.4. Key trends impacting the Cardiac biomarker testing market
3.4.1. Development of high sensitive biomarkers for risk stratification
3.4.2. Technological advancements in the cardiac biomarkers: Serum based biomarkers
3.4.3. Increasing demand for point of care cardiac diagnostics
3.5. Parent Market Overview
3.6. Key Forces Shaping Cardiac biomarker testing market
3.6.1. High bargaining power of suppliers
3.6.2. Low bargaining power of buyers
3.6.3. Low threat of new entrants
3.6.4. Low threat of substitutes
3.6.5. High intensity of rivalry
3.7. Value chain analysis
3.8. Pricing Analysis
3.8.1. Pricing Analysis, By Region, 2018 & 2025
3.9. Market evolution/Industry roadmap
3.10. Government regulations
3.11. Reimbursement issues
3.12. Patent Analysis
3.12.1. By Region (2016-2018)
3.12.2. By Applicant
3.13. Market share analysis
3.14. Case Studies
3.14.1. Case Study
3.15. Market dynamics
3.15.1. Drivers
3.15.1.1. Increasing prevalence of cardiovascular diseases
3.15.1.2. Cost effective
3.15.1.3. Non-invasive
3.15.1.4. Accuracy prediction
3.15.1.5. Technological advancements using cardiac biomarkers combinations
3.15.1.6. Increasing point of care (POC) testing
3.15.2. Restraints
3.15.2.1. Government Regulation
3.15.2.2. Conformation in result
3.15.2.3. Complex process
3.15.3. Opportunities
3.15.3.1. Personalized medicine
3.15.3.2. Point of care (POCT) testing using cardiac biomarkers
CHAPTER 4: CARDIAC BIOMARKER TESTING MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Creatine kinase (CK-MB)
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.3. Troponins
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Myoglobin
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Natriuretic peptides (BNP and NT-proBNP)
4.5.1. Key market trends and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
4.6. Ischemia modified albumin
4.6.1. Key market trends and opportunities
4.6.2. Market size and forecast
4.6.3. Market analysis, by country
4.7. Others
4.7.1. Key market trends and opportunities
4.7.2. Market size and forecast
4.7.3. Market analysis, by country
CHAPTER 5: CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Myocardial infarction
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. Congestive heart failure
5.3.1. Market size and forecast
5.3.2. Market analysis, by country
5.4. Acute coronary syndrome
5.4.1. Market size and forecast
5.4.2. Market analysis, by country
5.5. Atherosclerosis
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
5.6. Other applications
5.6.1. Market size and forecast
5.6.2. Market analysis, by country
CHAPTER 6: CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING
6.1. Overview
6.1.1. Market size and forecast
6.2. Point of care testing
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Laboratory testing
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
CHAPTER 7: CARDIAC BIOMARKER TESTING MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. North America market size and forecast, by type
7.2.3. North America market size and forecast, by application
7.2.4. North America market size and forecast, by location of testing
7.2.5. North America market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. U.S. market size and forecast, by type
7.2.5.1.2. U.S. market size and forecast, by application
7.2.5.1.3. U.S. market size and forecast, by location of testing
7.2.5.2. Canada
7.2.5.2.1. Canada market size and forecast, by type
7.2.5.2.2. Canada market size and forecast, by application
7.2.5.2.3. Canada market size and forecast, by location of testing
7.2.5.3. Mexico
7.2.5.3.1. Mexico market size and forecast, by type
7.2.5.3.2. Mexico market size and forecast, by application
7.2.5.3.3. Mexico market size and forecast, by location of testing
7.3. Europe
7.3.1. Key market trends and opportunities
7.3.2. Europe market size and forecast, by type
7.3.3. Europe market size and forecast, by application
7.3.4. Europe market size and forecast, by location of testing
7.3.5. Europe market size and forecast, by country
7.3.5.1. UK
7.3.5.1.1. UK market size and forecast, by type
7.3.5.1.2. UK market size and forecast, by application
7.3.5.1.3. UK market size and forecast, by location of testing
7.3.5.2. France
7.3.5.2.1. France market size and forecast, by type
7.3.5.2.2. France market size and forecast, by application
7.3.5.2.3. France market size and forecast, by location of testing
7.3.5.3. Germany
7.3.5.3.1. Germany market size and forecast, by type
7.3.5.3.2. Germany market size and forecast, by application
7.3.5.3.3. Germany market size and forecast, by location of testing
7.3.5.4. Rest of Europe
7.3.5.4.1. Rest of Europe market size and forecast, by type
7.3.5.4.2. Rest of Europe market size and forecast, by application
7.3.5.4.3. Rest of Europe market size and forecast, by location of testing
7.4. Asia-Pacific
7.4.1. Key market trends and opportunities
7.4.2. Asia-Pacific market size and forecast, by type
7.4.3. Asia-Pacific market size and forecast, by application
7.4.4. Asia-Pacific market size and forecast, by location of testing
7.4.5. Asia-Pacific market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. China market size and forecast, by type
7.4.5.1.2. China market size and forecast, by application
7.4.5.1.3. China market size and forecast, by location of testing
7.4.5.2. India
7.4.5.2.1. India market size and forecast, by type
7.4.5.2.2. India market size and forecast, by application
7.4.5.2.3. India market size and forecast, by location of testing
7.4.5.3. Australia
7.4.5.3.1. Australia market size and forecast, by type
7.4.5.3.2. Australia market size and forecast, by application
7.4.5.3.3. Australia market size and forecast, by location of testing
7.4.5.4. Japan
7.4.5.4.1. Japan market size and forecast, by type
7.4.5.4.2. Japan market size and forecast, by application
7.4.5.4.3. Japan market size and forecast, by location of testing
7.4.5.5. Rest of Asia-Pacific
7.4.5.5.1. Rest of Asia-Pacific market size and forecast, by type
7.4.5.5.2. Rest of Asia-Pacific market size and forecast, by application
7.4.5.5.3. Rest of Asia-Pacific market size and forecast, by location of testing
7.5. LAMEA
7.5.1. Key market trends and opportunities
7.5.2. LAMEA market size and forecast, by type
7.5.3. LAMEA market size and forecast, by application
7.5.4. LAMEA market size and forecast, by location of testing
7.5.5. LAMEA market size and forecast, by country
7.5.5.1. Latin America
7.5.5.1.1. Latin America market size and forecast, by type
7.5.5.1.2. Latin America market size and forecast, by application
7.5.5.1.3. Latin America market size and forecast, by location of testing
7.5.5.2. Middle East
7.5.5.2.1. Middle East market size and forecast, by type
7.5.5.2.2. Middle East market size and forecast, by application
7.5.5.2.3. Middle East market size and forecast, by location of testing
7.5.5.3. Africa
7.5.5.3.1. Africa market size and forecast, by type
7.5.5.3.2. Africa market size and forecast, by application
7.5.5.3.3. Africa market size and forecast, by location of testing
CHAPTER 8: COMPANY PROFILES
8.1. Abbott Laboratories
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. Becton, Dickinson and Company
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. BioMerieux
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.4. Bio-Rad Laboratories, Inc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.5. Danaher Corporation
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.6. F. HOFFMANN-LA ROCHE LTD.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Business performance
8.7. Siemens AG
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.8. Thermo Fisher Scientific, Inc.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Business performance
8.9. PerkinElmer Inc.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.10. Tosoh Corporation
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Business performance
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
